drugset / Trial / NCT03304054
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
Timeline
- Start
- 2018-04-18
- Primary completion
- 2020-01-31
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amifampridine | Small molecule | 10 mg | — |